(NASDAQ: MNOV) Medicinova's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 23.41%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 57.19%.
Medicinova's earnings in 2025 is -$11,159,151.On average, 2 Wall Street analysts forecast MNOV's earnings for 2025 to be -$13,242,486, with the lowest MNOV earnings forecast at -$14,713,874, and the highest MNOV earnings forecast at -$11,771,099.
In 2026, MNOV is forecast to generate -$13,978,180 in earnings, with the lowest earnings forecast at -$16,185,261 and the highest earnings forecast at -$11,771,099.